Literature DB >> 1459970

Restraint, seclusion, and clozapine.

A R Mallya1, P D Roos, K Roebuck-Colgan.   

Abstract

BACKGROUND: The effects of clozapine, an unconventional neuroleptic drug, on the use of restraint and seclusion in patients have not been extensively reported on in the United States.
METHOD: The records of 107 patients receiving clozapine in Missouri state mental hospitals were reviewed over a 13-month period for frequency and duration of restraint and seclusion.
RESULTS: During clozapine treatment, patients had fewer episodes of restraint and seclusion than previously. The duration of restraints and seclusions also decreased, starting the second month after the initiation of clozapine treatment.
CONCLUSION: For patients who were restrained or secluded before clozapine treatment, the decrease in the number and duration of restraint and seclusion episodes was dramatic.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1459970

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia: a cross-sectional study.

Authors:  S M Dursun; A Szemis; H Andrews; P Whitaker; M A Reveley
Journal:  J Psychiatry Neurosci       Date:  2000-09       Impact factor: 6.186

2.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 3.  Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series.

Authors:  Cana Aksoy Poyraz; Şenol Turan; Ömer Faruk Demirel; Nazife Gamze Usta Sağlam; Nazım Yıldız; Alaattin Duran
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

Review 4.  From Clozapine to Cognitive Remediation.

Authors:  Jason Quinn; Nathan J Kolla
Journal:  Can J Psychiatry       Date:  2016-07-10       Impact factor: 4.356

5.  Treatment-refractory schizophrenia.

Authors:  Asaf Caspi; Michael Davidson; Carol A Tamminga
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.